Kevin Kelly, Founder & CEO, Kelly Intelligence joins Julie Cooling, Founder & CEO, RIA Channel to discuss trends in healthcare 2.0, the gene editing revolution, and the investment case for Kelly CRISPR & Gene Editing Technology ETF (XDNA).
“We have entered into a new phase of healthcare focused on the curing diseases rather than treating them,” explains Kelly, calling the shift to Healthcare 2.0 “The next evolution of humanity.” The advancement of CRISPR technology, which seeks to treat diseases with a one-time gene editing technique, has the potential to revolutionize healthcare as we know it. While early versions of the CRISPR gene editing technology has been around for roughly three decades, development, testing and research has made major strides in the last ten years towards widespread commercialization.
The Kelly CRISPR & Gene Editing Technology ETF (XDNA) is a passive ETF designed to provide direct exposure to a concentrated portfolio of 20 – 25 companies central to the gene editing revolution. 70% of the ETF’s portfolio is allocated to companies that have the technology to edit DNA, 15% is allocated to companies that help bring the gene editing technology from development to commercialization, and 15% is allocated to companies specialized in sequencing. The ETF combines exposure to innovation with high growth potential to provide investors with cost-effective, targeted exposure to the companies leading this revolution in healthcare.
Kelly Intelligence is an SEC registered investment advisor that seeks to offer investors highly liquid exposure to companies identified as best-in-class among their theme or sector. Kevin Kelly, founder and CEO, is a recognized leader in ETF design and owner of extensive track record launching multi-billion dollar ETFs.